These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30714523)

  • 1. Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.
    Hussain A; Singh S; Das SS; Anjireddy K; Karpagam S; Shakeel F
    Curr Drug Deliv; 2019; 16(5):400-429. PubMed ID: 30714523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage Targeted Cellular Carriers for Effective Delivery of Anti-Tubercular Drugs.
    Agnihotri J; Singh S; Wais M; Pathak A
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):162-183. PubMed ID: 29219058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. State of the art and future directions in nanomedicine for tuberculosis.
    Dube A; Lemmer Y; Hayeshi R; Balogun M; Labuschagne P; Swai H; Kalombo L
    Expert Opin Drug Deliv; 2013 Dec; 10(12):1725-34. PubMed ID: 24102208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis: from molecular pathogenesis to effective drug carrier design.
    Dube D; Agrawal GP; Vyas SP
    Drug Discov Today; 2012 Jul; 17(13-14):760-73. PubMed ID: 22480870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current therapeutic delivery approaches using nanocarriers for the treatment of tuberculosis disease.
    Biswas B; Misra TK; Ray D; Majumder T; Bandyopadhyay TK; Bhowmick TK
    Int J Pharm; 2023 Jun; 640():123018. PubMed ID: 37149113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobead-based interventions for the treatment and prevention of tuberculosis.
    Griffiths G; Nyström B; Sable SB; Khuller GK
    Nat Rev Microbiol; 2010 Nov; 8(11):827-34. PubMed ID: 20938454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colloidal carriers: a rising tool for therapy of tuberculosis.
    Gupta S; Kumar P; Gupta MK; Vyas S
    Crit Rev Ther Drug Carrier Syst; 2012; 29(4):299-53. PubMed ID: 22746187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary Delivery of Anti-Tubercular Drugs Using Ligand Anchored pH Sensitive Liposomes for the Treatment of Pulmonary Tuberculosis.
    Bhardwaj A; Grobler A; Rath G; Goyal AK; Jain AK; Mehta A
    Curr Drug Deliv; 2016; 13(6):909-22. PubMed ID: 26718489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges.
    Ullah Z; Athar MT; Samad A
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):128-137. PubMed ID: 28990537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in nanotechnology for diagnosis and treatment of tuberculosis.
    Banyal S; Malik P; Tuli HS; Mukherjee TK
    Curr Opin Pulm Med; 2013 May; 19(3):289-97. PubMed ID: 23429097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Approaches and Future Prospects of Nanomedicine in Tuberculosis Therapy.
    Athar MT; Ullah Z
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):120-127. PubMed ID: 28443511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.
    Garg T; Rath G; Murthy RR; Gupta UD; Vatsala PG; Goyal AK
    Curr Pharm Des; 2015; 21(22):3076-89. PubMed ID: 26027577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nano-carriers for the Treatment of Tuberculosis.
    Gilani SJ; Ameeduzzafar ; Jafar M; Shakil K; Imam SS
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):95-106. PubMed ID: 28595544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Nanomedicines for the Treatment of Tuberculosis: Role of Nanocarriers and Functional Excipients.
    Samad A; Nazish I; Beg S
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):84. PubMed ID: 29745316
    [No Abstract]   [Full Text] [Related]  

  • 17. Tuberculosis: current state of knowledge: an epilogue.
    Leung CC; Lange C; Zhang Y
    Respirology; 2013 Oct; 18(7):1047-55. PubMed ID: 23837600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.
    Grotz E; Tateosian N; Amiano N; Cagel M; Bernabeu E; Chiappetta DA; Moretton MA
    Pharm Res; 2018 Sep; 35(11):213. PubMed ID: 30238168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.